Benzinga | Nov 1, 2021 08:42AM EDT

Argus Research Downgrades Bristol-Myers Squibb to Hold

Argus Research analyst David Toung downgrades Bristol-Myers Squibb (NYSE:BMY) from Buy to Hold.